Edmund Jessop | Medical Adviser
National Health Service

Edmund Jessop, Medical Adviser, National Health Service

Edmund Jessop has been practising public health for the NHS in England since 1981 in various jobs at district, regional and national levels. Since 2002, he has been medical adviser to the team which plans, funds and monitors services for patients with very rare disease. This has included decision making, and more recently close liaison with NICE, on the so-called “ultra-orphan” drugs as well as other highly specialised technologies. Edmund is UK representative to the EU Expert Group on Rare Disease. 

He was Vice President of the UK Faculty of Public Health (FPH) from 2011 to 2014 and Editor of the Journal of Public Health 1998 - 2007. He has taught courses on public health including health economics and health technology assessment for over 15 years.


Day 2, Nov 8 @ 08:35

A pan European study: The realities of orphan drug access

  • How do European countries differ in their value assessment to new orphan drugs?
  • What next steps are needed for more harmonized, comparable and rational evidence based decision-making in Europe?
Followed by live feedback from HTAs:Dr Karen Facey, Member, Scottish Health Technologies Group & Impact HTA - Co-Lead Investigator for WP10 - Appraisal of Orphan Medicinal ProductsEdmund Jessop, Medical Adviser, NHS EnglandSophia Brodin, Deputy Head of Department, Department of Value Based Pricing, TLV, The Dental and Pharmaceutical Benefits AgencySenior representative, H-AS, France
last published: 17/Oct/18 12:05 GMT

back to speakers

Follow us on


Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018


To Sponsor Or Exhibit


Andrew Mears
t/ +44 20 7092 1228


To Speak


Wing-Yun Cheung
t/ +44 20 7092 1172


To Register


Issa Mauthoor
t/ +44 20 7092 1257